Leerink Partnrs Expects Higher Earnings for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA) – Stock analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for shares of Kura Oncology in a research report issued to clients and investors on Thursday, November 21st. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings of ($2.19) per share for the year, up from their prior estimate of ($2.51). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q4 2024 earnings at ($0.39) EPS and FY2025 earnings at $0.70 EPS.

A number of other analysts have also commented on the stock. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research note on Thursday. Bank of America cut their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday. Wedbush reaffirmed an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research report on Monday, November 4th. HC Wainwright upped their price target on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Jefferies Financial Group dropped their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.38.

Kura Oncology Price Performance

NASDAQ KURA opened at $10.80 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a 1 year low of $9.06 and a 1 year high of $24.17. The stock has a market capitalization of $839.81 million, a P/E ratio of -4.58 and a beta of 0.86. The business’s fifty day moving average is $17.88 and its two-hundred day moving average is $19.67.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in shares of Kura Oncology by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after buying an additional 41,535 shares during the last quarter. Barclays PLC increased its position in Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after acquiring an additional 84,563 shares during the period. Jane Street Group LLC raised its stake in Kura Oncology by 36.7% during the 3rd quarter. Jane Street Group LLC now owns 126,085 shares of the company’s stock valued at $2,464,000 after purchasing an additional 33,848 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in Kura Oncology in the 3rd quarter worth $146,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Kura Oncology during the 3rd quarter worth about $3,695,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.